Results 131 to 140 of about 63,667 (225)

Tenofovir-associated bone density loss

Therapeutics and Clinical Risk Management, 2009
Iwen F Grigsby1,2,3,4,5, Lan Pham1,2,4, Louis M Mansky3,4,5, Raj Gopalakrishnan3,4, Kim C Mansky1,2,41Division of Orthodontics, 2Department of Developmental and Surgical Sciences, 3Department of Diagnostic and Biological Sciences, 4MinnCResT Program ...
Iwen F Grigsby, Lan Pham, Louis M Mansky, et al   +3 more
doaj  

Considerations for the Use of AAV‐based Gene Therapy in HIV‐Positive Individuals With Haemophilia

Haemophilia, Volume 32, Issue 3, Page 584-592, May/June 2026.
ABSTRACT Introduction There is a high prevalence of human immunodeficiency virus (HIV) infection among the haemophilia community due to treatment in the 1970s and 1980s with contaminated clotting factor. Lifelong treatment regimens for haemophilia and HIV are burdensome alone and pose a particular challenge for individuals living with both conditions ...
Jürgen K. Rockstroh, Julia C. Stingl, Marco Stadler, Anja Reichert, Heiner Wedemeyer, Johannes Oldenburg   +5 more
wiley   +1 more source

Characteristics of a cohort of high-risk men who have sex with men on pre-exposure prophylaxis reporting transgender sexual partners. [PDF]

, 2019
Transgender people continue to be at high-risk for HIV acquisition, but little is known about the characteristics of their sexual partners. To address this gap, we examined sociodemographic and sexual characteristics of cisgender men who have sex with ...
Blumenthal, Jill S, Corado, Katya, Dube, Michael P, Ellorin, Eric, Hassan, Adiba, Moore, David J, Morris, Sheldon R, Wertheim, Joel O   +7 more
core  

Exploring the impact of Cabotegravir‐Rilpivirine long‐acting on weight gain, body composition and quality of life in adults living with HIV

HIV Medicine, Volume 27, Issue 5, Page 727-739, May 2026.
Abstract Introduction Long‐acting injectable antiretroviral therapy (ART) with Cabotegravir (CAB) and Rilpivirine (RPV) offers an alternative to daily oral regimens, improving adherence and patient satisfaction. However, its impact on body composition and metabolism remains underexplored.
Andrea De Vito, Andrea Marongiu, Antonella Cano, Mariangela Puci, Agnese Colpani, Susanna Maria Nuvoli, Maria Grazia Catte, Giulia Moi, Maria Antonietta Deledda, Sergio Uzzau, Giovanni Sotgiu, Franca Deriu, Angela Spanu, Giordano Madeddu   +13 more
wiley   +1 more source

Virological outcomes with Bictegravir/Emtricitabine/Tenofovir alafenamide (B/F/TAF) in people previously treated with darunavir‐based antiretroviral therapy

HIV Medicine, Volume 27, Issue 5, Page 803-808, May 2026.
Abstract Background Darunavir‐based antiretroviral therapy (ART) is commonly used in people with HIV who experience adherence challenges and/or have complex resistance patterns. Changes in ART commissioning have led to an increased use of Bictegravir/Emtricitabine/Tenofovir alafenamide (B/F/TAF) in these populations despite limited real‐world outcome ...
Rhianna Sheridan, Yasmin Osei‐Kuffour Ekert, Lucy Campbell, Mark Zuckerman, Sally Hawkins, Kate Childs, Frank A. Post   +6 more
wiley   +1 more source

Pharmacovigilance study of INSTIs associated with weight gain and glucose/lipid metabolism adverse events based on the FDA adverse event reporting system

HIV Medicine, Volume 27, Issue 5, Page 749-760, May 2026.
Abstract Objective Integrase strand transfer inhibitors (INSTIs) are widely used in antiretroviral therapy (ART) for people with HIV due to their efficacy and tolerability. However, concerns about weight gain and metabolic disturbances have emerged.
Leidan Zhang, Ling Chen, Jia Tang, Xiaosheng Liu, Liyuan Zheng, Fada Wang, Xin Huang, Wei Cao, Taisheng Li   +8 more
wiley   +1 more source

Achieving reimbursable PrEP is insufficient to increase and diversify the users attending community‐based services

HIV Medicine, Volume 27, Issue 5, Page 785-795, May 2026.
Abstract Objectives The reimbursement of HIV pre‐exposure prophylaxis (PrEP) in Italy was expected to increase uptake and diversify users. We assessed changes in PrEP initiation patterns before and after reimbursement at a community‐based service. Methods We conducted a monocentric retrospective cohort study that included all individuals who initiated ...
Enrico Caruso, Alessandro Tavelli, Anna De Bona, Nicoletta Frattini, Davide Moschese, Camilla Muccini, Daniele Tesoro, Alessandro Guido Soria, Alessandra Bianchi, Antonella D' Arminio Monforte, Massimo Cernuschi, Roberto Rossotti   +11 more
wiley   +1 more source

Cost‐Effectiveness of Interventions to Improve Retention in Care for Chronic Hepatitis B in the United States

Journal of Viral Hepatitis, Volume 33, Issue 5, May 2026.
ABSTRACT Monitoring and retention in care remain suboptimal for patients diagnosed with chronic hepatitis B (CHB) infection with only a minority receiving consistent follow‐up. This study evaluates the cost‐effectiveness of interventions aimed at improving long‐term monitoring and retention in care among diagnosed CHB. A Markov model simulated outcomes
Irene Starinieri, Amit Chitnis, Robert J. Wong, Emily Yette, Hang Pham, Amy S. Tang, Samuel So, Mehlika Toy   +7 more
wiley   +1 more source

Reply to: “Promising Drugs Require Proper Testing”: Let's Not Confuse Pharmacodynamics With Clinical Efficacy

Clinical and Translational Science, Volume 19, Issue 5, May 2026.
Inès Ben Ghezala, Marc Bardou
wiley   +1 more source

Promising Drugs Require Proper Testing

Clinical and Translational Science, Volume 19, Issue 5, May 2026.
Jean‐Jacques Parienti
wiley   +1 more source